New treatment to protect the heart during breast cancer therapy
Definitive (GLP) Toxicity and Toxicology Studies for a Novel Small Molecule for Protection Against Cardiotoxicity in Triple Negative Breast Cancer
This study is testing a new medicine that works with standard chemotherapy to help treat triple negative breast cancer while aiming to protect your heart from damage, so you can have a safer and more effective treatment experience.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Novomedix, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-10921449 on NIH RePORTER |
What this research studies
This research focuses on developing a novel small molecule that works alongside traditional chemotherapy drugs, specifically anthracyclines like Doxorubicin, to treat triple negative breast cancer (TNBC). The goal is to improve treatment outcomes for patients while significantly reducing the risk of heart damage associated with these chemotherapy agents. By targeting the cardiotoxic effects of anthracyclines, this research aims to enhance the safety and effectiveness of breast cancer treatments. Patients participating in this research may receive a new therapy that could help mitigate the long-term health risks of their cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer who are undergoing or have undergone treatment with anthracycline chemotherapy.
Not a fit: Patients with non-breast cancer diagnoses or those who do not have triple negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer chemotherapy options for breast cancer patients, reducing the risk of heart-related complications.
How similar studies have performed: Previous research has shown promise in developing therapies that reduce cardiotoxicity in cancer treatments, suggesting potential for success in this novel approach.
Where this research is happening
San Diego, United States
- Novomedix, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Swindlehurst, Cathy a — Novomedix, INC.
- Study coordinator: Swindlehurst, Cathy a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.